UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

International journal of molecular sciences, 2021-03, Vol.22 (7), p.3464

2021

Volltextzugriff (PDF)

Genomic alterations of ERBB receptors in cancer: clinical implications

Oncotarget, 2017-12, Vol.8 (69), p.114371-114392

2017

Volltextzugriff (PDF)

Current Advances in the Treatment of BRAF-Mutant Melanoma

Cancers, 2020-02, Vol.12 (2), p.482

2020

Volltextzugriff (PDF)

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers

PloS one, 2023-05, Vol.18 (5), p.e0285251

2023

Volltextzugriff (PDF)

HER3 signaling and targeted therapy in cancer

Oncology Reviews, 2018-05, Vol.12 (1), p.355-355

2018

Volltextzugriff (PDF)

Non-Muscle Myosin II A: Friend or Foe in Cancer?

International journal of molecular sciences, 2024-08, Vol.25 (17), p.9435

2024

Volltextzugriff (PDF)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma

Cancers, 2021-11, Vol.13 (22), p.5863

2021

Volltextzugriff (PDF)

HER3 Alterations in Cancer and Potential Clinical Implications

Cancers, 2022-12, Vol.14 (24), p.6174

2022

Volltextzugriff (PDF)

Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model

PloS one, 2012-03, Vol.7 (3), p.e33633

2012

Volltextzugriff (PDF)

BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels

Cancers, 2020-06, Vol.12 (6), p.1661

2020

Volltextzugriff (PDF)

Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth

International journal of molecular sciences, 2021-02, Vol.22 (4), p.2088

2021

Volltextzugriff (PDF)

Osteopontin as a therapeutic target for cancer

Expert opinion on therapeutic targets, 2014-08, Vol.18 (8), p.883-895

2014

Volltextzugriff (PDF)

Oxidative Cyclization‐Induced Activation of a Phosphoinositide 3‐Kinase Inhibitor for Enhanced Selectivity of Cancer Chemotherapeutics

ChemMedChem, 2019-11, Vol.14 (22), p.1933-1939

2019

Volltextzugriff (PDF)

Abstract 1284: Resistance to BRAF and MEK inhibitors in BRAFV600E mutant melanoma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1284-1284

2019

Volltextzugriff (PDF)

HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer

Molecular carcinogenesis, 2024-08, Vol.63 (8), p.1528-1541

2024

Volltextzugriff (PDF)

Abstract P5-10-05: HER2 inhibition increases non-muscle myosin IIa to promote tumorigenesis in HER2+ breast cancers

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-10-05

2022

Volltextzugriff (PDF)

Abstract 4900: Reactive oxygen species scavenger extends the efficacy of BRAF inhibitors in BRAF-mutant melanoma

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4900-4900

2018

Volltextzugriff (PDF)

RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells

Anti-cancer drugs, 2023-04, Vol.34 (4), p.519

2023

Volltextzugriff (PDF)

Abstract 5914: Non-muscle myosin IIA as a promising therapeutic target in breast cancer

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.5914-5914

2024

Volltextzugriff (PDF)

Abstract 4205: The role of non-muscle myosin IIA in HER2+ breast cancers

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4205-4205

2020

Volltextzugriff (PDF)

Abstract 389: Role of her3 signaling pathways in er+ and her2+ breast cancers

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.389-389

2019

Volltextzugriff (PDF)

Abstract 1894: Role of IGF1R in mediating resistance to MAPK pathway inhibitors in BRAF-mutant melanoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1894-1894

2020

Volltextzugriff (PDF)

Abstract P3-10-04: Efficacy of RIDRPI103, a reactive oxygen species (ROS) activated prodrug in treatment of breast cancer

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P3-P3-10-04

2020

Volltextzugriff (PDF)

Abstract 1896: Patient-derived HER3 mutations transform ER+ and HER2+ breast cancer cells via MAPK pathway activation

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1896-1896

2018

Volltextzugriff (PDF)

Abstract 7150: Molecular insights into the oncogenic influence between mutant HER3, mutant KRAS, and their synergistic interplay in colorectal cancer pathogenesis

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.7150-7150

2024

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(55)
Berichte
(1)

Sprache

Englisch
(56)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

Genomic alterations of ERBB receptors in cancer: clinical implications

Current Advances in the Treatment of BRAF-Mutant Melanoma

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers

HER3 signaling and targeted therapy in cancer

Non-Muscle Myosin II A: Friend or Foe in Cancer?

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma

HER3 Alterations in Cancer and Potential Clinical Implications

Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model

BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels

Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth

Osteopontin as a therapeutic target for cancer

Oxidative Cyclization‐Induced Activation of a Phosphoinositide 3‐Kinase Inhibitor for Enhanced Selectivity of Cancer Chemotherapeutics

Abstract 1284: Resistance to BRAF and MEK inhibitors in BRAFV600E mutant melanoma

HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer

Abstract P5-10-05: HER2 inhibition increases non-muscle myosin IIa to promote tumorigenesis in HER2+ breast cancers

Abstract 4900: Reactive oxygen species scavenger extends the efficacy of BRAF inhibitors in BRAF-mutant melanoma

RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells

Abstract 5914: Non-muscle myosin IIA as a promising therapeutic target in breast cancer

Abstract 4205: The role of non-muscle myosin IIA in HER2+ breast cancers

Abstract 389: Role of her3 signaling pathways in er+ and her2+ breast cancers

Abstract 1894: Role of IGF1R in mediating resistance to MAPK pathway inhibitors in BRAF-mutant melanoma

Abstract P3-10-04: Efficacy of RIDRPI103, a reactive oxygen species (ROS) activated prodrug in treatment of breast cancer

Abstract 1896: Patient-derived HER3 mutations transform ER+ and HER2+ breast cancer cells via MAPK pathway activation

Abstract 7150: Molecular insights into the oncogenic influence between mutant HER3, mutant KRAS, and their synergistic interplay in colorectal cancer pathogenesis

Suchergebnisse filtern